Published in Bioorg Med Chem on August 09, 2010
Crystal structure of 3,5-dimeth-oxy-2-[5-(naphthalen-1-yl)-4,5-di-hydro-1H-pyrazol-3-yl]phenol. Acta Crystallogr E Crystallogr Commun (2015) 0.75
Crystal structure of 3-meth-oxy-2-[5-(naphthalen-1-yl)-4,5-di-hydro-1H-pyrazol-3-yl]phenol. Acta Crystallogr E Crystallogr Commun (2015) 0.75
Design, synthesis, in silico toxicity prediction, molecular docking, and evaluation of novel pyrazole derivatives as potential antiproliferative agents. EXCLI J (2016) 0.75
Synthesis and Anti-Inflammatory Activity of Some O-Propargylated-N-acetylpyrazole Derived from 1,3-Diarylpropenones. Int J Med Chem (2016) 0.75
3-Meth-oxy-2-[5-(naphthalen-2-yl)-4,5-di-hydro-1H-pyrazol-3-yl]phenol. Acta Crystallogr Sect E Struct Rep Online (2014) 0.75
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem (2005) 1.52
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res (2003) 1.45
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res (2011) 1.40
Development and therapeutic impact of HDAC6-selective inhibitors. Biochem Pharmacol (2012) 1.36
Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues. Bioorg Med Chem Lett (2007) 1.30
Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes (2011) 1.29
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther (2009) 1.28
New potential anticancer agents based on the anthranilic acid scaffold: synthesis and evaluation of biological activity. J Med Chem (2005) 1.25
Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem (2011) 1.15
Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol (2007) 1.11
Synthesis and antiproliferative activity of 2,6-dibenzylamino-3,5-dicyanopyridines on human cancer cell lines. Eur J Med Chem (2005) 1.08
Triplex formation on DNA targets: how to choose the oligonucleotide. Biochemistry (2008) 1.03
Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med (2011) 1.02
A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res (2010) 1.00
Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res (2011) 1.00
Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol (2010) 0.99
Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem (2004) 0.99
Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J Biol Chem (2004) 0.99
Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem (2006) 0.97
Novel combretastatin analogues endowed with antitumor activity. J Med Chem (2006) 0.97
Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry (2002) 0.96
The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci (2009) 0.96
Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. J Liposome Res (2004) 0.95
Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res (2005) 0.95
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res (2003) 0.94
The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. Chembiochem (2010) 0.94
Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther (2005) 0.93
Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J Med Chem (2005) 0.92
Synthesis and biological activity of fluorinated combretastatin analogues. J Med Chem (2008) 0.92
Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis (2007) 0.92
Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. J Med Chem (2008) 0.91
A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem (2003) 0.90
Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res (2005) 0.90
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects. Biochem Pharmacol (2012) 0.90
Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors. Bioorg Med Chem (2010) 0.89
Chemotherapy-induced allodinia: neuroprotective effect of acetyl-L-carnitine. In Vivo (2005) 0.89
RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BMC Cancer (2013) 0.88
Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol (2010) 0.88
Synthesis and in vitro antitumoral activity of new N-phenyl-3-pyrrolecarbothioamides. Bioorg Med Chem (2003) 0.88
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents. Clin Cancer Res (2011) 0.88
Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. Bioorg Med Chem (2005) 0.88
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem (2003) 0.87
Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem (2007) 0.87
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology (2004) 0.87
Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen. Eur J Pharmacol (2013) 0.86
Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother (2002) 0.86
Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol (2006) 0.86
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968. Mol Cancer Ther (2008) 0.86
Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. J Enzyme Inhib Med Chem (2012) 0.85
Synthesis of benzo[1,2-d;3,4-d']diimidazole and 1H-pyrazolo[4,3-b]pyridine as putative A2A receptor antagonists. Org Biomol Chem (2007) 0.85
ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood (2003) 0.85
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968. Eur J Cancer (2008) 0.85
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem (2005) 0.84
Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells. Blood (2002) 0.84
Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem (2008) 0.84
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J Med Chem (2004) 0.84
Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. Clin Cancer Res (2010) 0.84
Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett (2009) 0.83
Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res (2002) 0.83
Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity. J Med Chem (2010) 0.83
Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One (2011) 0.83
Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J Med Chem (2006) 0.82
Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. Bioorg Med Chem (2004) 0.82
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models. Biochem Pharmacol (2003) 0.82
Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore. Bioorg Med Chem (2007) 0.82
The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis (2008) 0.82
Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of its role in apoptosis. Cancer Biol Ther (2006) 0.82
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models. Cancer Chemother Pharmacol (2012) 0.81
Sequence-specific targeting of IGF-I and IGF-IR genes by camptothecins. FASEB J (2010) 0.81
Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significance for the cytotoxic and antiproliferative activity. Mol Cancer Ther (2008) 0.80
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors. J Med Chem (2014) 0.80
Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response. Neoplasia (2005) 0.80
Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett (2007) 0.80
Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90. J Med Chem (2011) 0.79
The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors. J Biol Chem (2011) 0.79